- Home
- FENC
as 11-15-2024 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 181.7M | IPO Year: | 2001 |
| Target Price: | $14.00 | AVG Volume (30 days): | 116.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $11.92 | Next Earning Date: | 11-07-2024 |
| Revenue: | $49,348,000 | Revenue Growth: | 278.09% |
| Revenue Growth (this year): | 116.5% | Revenue Growth (next year): | 17.49% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Oct 31 '24 | Sell | $4.31 | 2,431 | $10,477.61 | 66,432 | |
| RALLIS CHRIS A | FENC | Director | Oct 8 '24 | Sell | $4.53 | 1,406 | $6,369.18 | 48,623 | |
| Raykov Rosty | FENC | Director | Sep 30 '24 | Sell | $4.94 | 2,431 | $12,009.14 | 66,432 | |
| Raykov Rosty | FENC | Director | Aug 31 '24 | Sell | $5.52 | 2,431 | $13,419.12 | 66,432 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
Simply Wall St.
5 days ago
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
8 days ago
Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
MT Newswires
10 days ago
Fennec Pharmaceuticals Q3 Loss Widens as Expenses Rise
GlobeNewswire
10 days ago
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
17 days ago
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Simply Wall St.
19 days ago
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30%
MT Newswires
20 days ago
Fennec Pharmaceuticals Names Chief Medical, Commercial, and Strategy Officers
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.